Ariad, MolecularMD Sign Deal For Companion Diagnostic
This article was originally published in The Pink Sheet Daily
The oncology company plans to have a diagnostic test available to detect the T315I mutation in leukemia patients.
You may also be interested in...
Cephalon Inc. announced March 29 that it has struck an agreement with the Australia-based biopharma ChemGenex Pharmaceuticals Ltd. to pay A$159 million ($US $163 million) for the piece of the company it doesn't already own
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.